WallStreetZenWallStreetZen

NASDAQ: PLRX
Pliant Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their PLRX stock forecasts and price targets.

Forecast return on equity

Is PLRX forecast to generate an efficient return?

Company
-36.97%
Industry
25.06%
Market
177.77%
PLRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PLRX forecast to generate an efficient return on assets?

Company
-28.61%
Industry
23.99%
PLRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PLRX earnings per share forecast

What is PLRX's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.46
Avg 2 year Forecast
-$1.38
Avg 3 year Forecast
-$1.09

PLRX revenue forecast

What is PLRX's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

PLRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PLRX$0.90N/AN/A
XLO$8.55N/AN/A
GANX$1.26$6.50+415.87%Strong Buy
CNTB$0.91$5.43+499.23%Strong Buy
GOSS$8.77$134.48+1,433.41%Buy
View Top Biotech Stocks

Pliant Therapeutics Stock Forecast FAQ

What is PLRX's earnings growth forecast for 2026-2028?

(NASDAQ: PLRX) Pliant Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.8%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.78%.

Pliant Therapeutics's earnings in 2026 is -$92,289,000.On average, 6 Wall Street analysts forecast PLRX's earnings for 2026 to be -$90,480,276, with the lowest PLRX earnings forecast at -$89,204,685, and the highest PLRX earnings forecast at -$91,675,369. On average, 6 Wall Street analysts forecast PLRX's earnings for 2027 to be -$85,743,251, with the lowest PLRX earnings forecast at -$95,879,865, and the highest PLRX earnings forecast at -$61,116,912.

In 2028, PLRX is forecast to generate -$67,792,093 in earnings, with the lowest earnings forecast at -$87,384,181 and the highest earnings forecast at -$43,562,055.

If you're new to stock investing, here's how to buy Pliant Therapeutics stock.

What is PLRX's revenue growth forecast for 2026-2028?

(NASDAQ: PLRX) Pliant Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.

Pliant Therapeutics's revenue in 2026 is $0.On average, 5 Wall Street analysts forecast PLRX's revenue for 2026 to be $0, with the lowest PLRX revenue forecast at $0, and the highest PLRX revenue forecast at $0. On average, 5 Wall Street analysts forecast PLRX's revenue for 2027 to be $0, with the lowest PLRX revenue forecast at $0, and the highest PLRX revenue forecast at $0.

In 2028, PLRX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is PLRX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: PLRX) forecast ROA is -28.61%, which is lower than the forecast US Biotechnology industry average of 23.99%.

What is PLRX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: PLRX) Pliant Therapeutics's current Earnings Per Share (EPS) is -$1.49. On average, analysts forecast that PLRX's EPS will be -$1.46 for 2026, with the lowest EPS forecast at -$1.44, and the highest EPS forecast at -$1.48. On average, analysts forecast that PLRX's EPS will be -$1.38 for 2027, with the lowest EPS forecast at -$1.55, and the highest EPS forecast at -$0.99. In 2028, PLRX's EPS is forecast to hit -$1.09 (min: -$1.41, max: -$0.70).

What is PLRX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: PLRX) forecast ROE is -36.97%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.